Drug use in sports: A veritable arena for pharmacists

Journal of the American Pharmacists Association

Volumn 44, Issue 4, 2004, Pages 501-516

  Ambrose, Peter J ^a,b,c,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^c Datalys Center for Sports Injury Research and Prevention Inc   (United States)

^d National Center for Drug Free Sport   (United States)

^e XXVII Olympiad   (Australia)

Author keywords

Doping; Doping control; Drug abuse; Ergogenic; Pharmacists; Sports

Indexed keywords

CLASSIFICATION; DIET SUPPLEMENTATION; DOPING; ETHICS; LEGAL ASPECT; MEDICAL ETHICS; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PROFESSIONAL STANDARD; REVIEW; SELF MEDICATION; UNITED STATES;

DIETARY SUPPLEMENTS; DOPING IN SPORTS; ETHICS, PHARMACY; PATIENT EDUCATION; PROFESSIONAL ROLE; SELF MEDICATION; UNITED STATES;

EID: 16544385037     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345041475698     Document Type: Article

References (127)

1. Price KO, Huff PS, Isetts BJ, Goldwire MA. University-based sports pharmacy program. Am J Health Syst Pharm. 1995;52:302-9.
2. Wagner JC, Ulrich LR, McKean DC, Blankenbaker RG. Pharmaceutical services at the tenth Pan American Games. Am J Hosp Pharm. 1989;46:2023-7.
3. Ambrose PJ. Doping control in sports-a perspective from the 1996 Olympic Games. Am J Health Syst Pharm. 1997;54:1053-7.
4. Kuschell J. Pharmacists at the Olympics. Drug Topics. 1996;140(16):12.
5. Klink B. Are you dispensing to athletes? Beware of banned substances. Drug Topics. 1999;143(9):30-7.
6. Young D. Pharmacists play pivotal roles at Olympic Games. Am J Health Syst Pharm. 2002;59:326-30.
7. Page D. Pharmacists play role in making sure athletes are running clean. Drug Topics. 2000;144(18):33.
8. Korporaal G, Beikoff K, Bita N. Sydney 2000 catalogue of disgrace. The Daily Telegraph [Sydney, Australia]. 2000(Sept. 28):4.
9. Bahrke MS, Yesalis CE. The future of performance-enhancing substances in sport. Phys Sportsmed. 2002;30(11):51-3.
10. Birchard K. Olympic committee bans doctor after doping case. Lancet. 2000;356:1171.
11. Beikoff K, Bita N. Court appeal on drug ruling: gymnast loses gold over cold pill. The Daily Telegraph [Sydney, Australia]. 2000(Sept. 27):2.
12. The World Anti-Doping Code. The 2004 Prohibited List. Accessed at: www.wada-ama.org/ docs/web/standards-harmonization/code/list-2004.pdf, October 20, 2003.
13. Corrigan B, Kazlauskas R. Medication use in athletes selected for doping control at the Sydney Olympics (2000). Clin J Sport Med. 2003;13:33-40.
14. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. Adv Intern Med. 1991;36:399-424.
15. Rosenberg JM, Fuentes RJ, Woolley, et al. Questions and answers-what athletes commonly ask. In: Fuentes RJ, Rosenberg JM, eds. Athletic drug reference '99. Durham, N.C.: Clean Data, Inc.; 1999:1-128.
16. United States Anti-Doping Agency. 2004 Guide to prohibited classes of substances and prohibited methods of doping. Accessed at: www.usantidoping.org/ files/USADA-Guide.pdf, June 2, 2004.
17. Gordon B. Grecian athletic training in the third century (AD). Ann Med Hist. 1935;6:513.
18. Tuffs A. Doped East German athletes to receive compensation. BMJ. 2002;324:1544.
19. World Anti-Doping Agency. Accessed at: www.wada-ama.org/en/t1.asp, July 10, 2003.
20. United States Anti-Doping Agency. Accessed at: www.usantidoping.org, July 10, 2003.
21. The National Center for Drug Free Sport, Inc. Accessed at: www.drugfreesport.com/home.htm, July 10, 2003.
22. The National Collegiate Athletic Association, NCAA 2003-04 Banned-Drug Classes. Accessed at: www.ncaa.org/sports-sciences/drugtesting/banned-list.html, October 20, 2003.
23. Wagner JC. Substance-abuse policies and guidelines in amateur and professional athletics. Am J Hosp Pharm. 1987;44:305-10.
24. Gall SL, Duda M, Giel D, Rogers CC. Who tests which athletes for what drugs? Phys Sportsmed. 1988;16(2):155-61.
25. Ambrose PJ. Synephrine (Citrus aurantium). Drug Free Sport Insight. 2003;2(12):2.
26. The National Collegiate Athletic Association. NCAA study of substance use habits of college student-athletes. June 2001. Accessed at: www.ncaa.org/library/research/substance-use-habits/2001/substance-use-habits. pdf, May 30, 2003.
27. Prendergast HM, Bannen T, Erickson TB, Honore KR. The toxic torch of the modern Olympic Games. Vet Hum Toxicol. 2003;45:97-102.
28. Catlin DH, Kammerer RC, Hatton CK, et al. Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984. Clin Chem. 1987;33:319-27.
29. Verducci T. Totally juiced. Sports Illustrated. 2002;96:34-48.
30. Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacologic basis of therapeutics. 10th ed. New York, N.Y.: McGraw-Hill; 2001:215-68.
31. Bouchard R, Weber AR, Geiger JD. Informed decision-making on sympathomimetic use in sport and health. Clin J Sport Med. 2002;12:209-24.
32. Uryasz F. NFL bans ephedrine. Drug Free Sport Insight. 2002;1(9):1.
33. Graham TE, Spriet LL. Performance and metabolic responses to a high caffeine dose during prolonged exercise. J Appl Physiol. 1991;71:2292-8.
34. Jackman M, Wendling P, Friars D, Graham TE. Metabolic, catecholamine, and endurance responses to caffeine during intense exercise. J Appl Physiol. 1996;81:1658-63.
35. Graham TE. Caffeine and exercise: metabolism, endurance and performance. Sports Med. 2001;31:785-807.
36. Trice I, Haymes EM. Effects of caffeine ingestion on exercise-induced changes during high-intensity, intermittent exercise. Int J Sport Nutr. 1995;5:37-44.
37. Van Soeren MH, Graham TE. Effect of caffeine on metabolism, exercise endurance, and catecholamine responses after withdrawal. J Appl Physiol. 1998;85:1493-501.
38. Greer F, McLean C, Graham TE. Caffeine, performance, and metabolism during repeated Wingate exercise tests. J Appl Physiol. 1998;85:1502-8.
39. Durrant KL. Known and hidden sources of caffeine in drug, food and natural products. J Am Pharm Assoc. 2002;42:625-37.
40. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med. 2002;32:285-96.
41. Rosenberg JM, Fuentes RJ. Anabolic steroids and the athlete. In: Fuentes RJ, Rosenberg JM, eds. Athletic Drug Reference '99. Durham, N.C.: Clean Data, Inc.; 1999:131-60.
42. Hartgens F, Lichtenbelt WDVM, Ebbing S, et al. Androgenic-anabolic steroid-induced body changes in strength athletes. Phys Sportsmed. 2001;29(1):49-66.
43. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335:1-7.
44. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med. 1984;12:469-84.
45. Yesalis CE III, Herrick RT, Buckley WE, et al. Self-reported use of anabol-ic- androgenic steroids by elite power lifters. Phys Sportmed. 1988;16(12):91-100.
46. Dezelski TL, Toohey JV, Shaw RS. Non-medical drug use behaviour at five United States universities: a 15-year study. Bull Narc. 1985;37:49-53.
47. Greydanus DE, Patel DR. Sports doping in the adolescent athlete: the hope, hype and hyperbole. Pediatr Clin N Am. 2002;49:829-55.
48. Congeni J, Miller S. Supplements and drugs used to enhance athletic performance. Pediatr Clin N Am. 2002;49:435-61.
49. Tanner SM, Miller DW, Alongi C. Anabolic steroid use by adolescents: prevalence, motives, and knowledge of risks. Clin J Sport Med. 1995;5:108-15.
50. DuRant RH, Rickert VI, Ashworth CS, et al. Use of multiple drugs among adolescents who use anabolic steroids. N Engl J Med. 1993;328:992-6.
51. Buckley WE, Yesalis CE III, Friedl KE, et al. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA. 1988;260:3441-5.
52. Scott DM, Wagner JC, Barlow TW. Anabolic steroid use among adolescents in Nebraska schools. Am J Health Syst Pharm. 1996;53:2068-72.
53. Bahrke MS, Yesalis CE, Kopstein AN, Stephens JA. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000;29:397-405.
54. Pärssinen M, Seppälä T. Steroid use and long-term health risks in former athletes. Sports Med. 2002;32:83-94.
55. Snyder PJ. Androgens. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, N.Y.: McGraw-Hill; 2001:1635-48.
56. Vander A, Sherman J, Luciano D. Human physiology: the mechanisms of body function. 7th ed. Boston, Mass.: WCB/McGraw-Hill; 1998.
57. American Academy of Pediatrics Committee on Sports Medicine and Fitness. Adolescents and anabolic steroids: a subject review. Pediatrics. 1997;99:904-8.
58. O'Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust. 2000;173:323-7.
59. Friedl KE, Yesalis CE. Self-treatment of gynecomastia in bodybuilders who use anabolic steroids. Phys Sportsmed. 1989;17(3):67-79.
60. Bahrke MS, Yesalis CE III, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids: an update. Sports Med. 1996;22:367-90.
61. Huie MJ. An acute myocardial infarction occurring in an anabolic steroid user. Med Sci Sports Exerc. 1994;26:408-13.
62. Parker KL, Schimmer BP. Pituitary hormones and their hypothalamic releasing factors. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, N.Y.: McGraw-Hill; 2001:1541-61.
63. Yarasheski KE, Campbell JA, Smith K, et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol. 1992;262:E261-7.
64. Yarasheski KE, Zachwieja JJ, Angelopoulos TJ, Brier DM. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol. 1993;74:3073-6.
65. Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol. 1995;268:E268-76.
66. Deyssig R, Frish H, Blum WF, Waldhor T. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinologica. 1993;128:313-8.
67. Dean H. Does exogenous growth hormone improve athletic performance? Clin J Sport Med. 2002:12:250-3.
68. Varlet-Marie E, Gaudard A, Audran M, Bressolle F. Pharmacokinetics/ pharmacodynamics of recombinant human erythropoietins in doping control. Sports Med. 2003;33:301-15.
69. Gaudard A, Varlet-Marie E, Bressolle F, Audran M. Drugs for increasing oxygen transport and their potential use in doping: a review. Sports Med. 2003;33:187-212.
70. Lage JMM, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis. Neurology. 2002;58:665.
71. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, N.Y.: McGraw-Hill; 2001:1649-77.
72. Kruse P, Ladefoged J, Nielson U, et al. Beta-blockade used in precision sports: effect on pistol shooting performance. J Appl Physiol. 1986;61:417-20.
73. Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology. 1984:34:221-2.
74. Weiler JM, Ryan EJ III. Asthma in United States Olympic athletes who participated in the 1998 Olympic Winter Games. J Allergy Clin Immunol. 2000;106:267-71.
75. Wilber RL, Rundell KW, Szmedra L, et al. Incidence of exercise-induced bronchospasm in Olympic winter sport athletes. Med Sci Sports Exerc. 2000;32:732-7.
76. McKenzie DC, Stewart IB, Fitch KD. The asthmatic athlete, inhaled beta agonists, and performance. Clin J Sport Med. 2002;12:225-8.
77. Schnirring L. IOC asks athletes for asthma proof: request raises complex issues. Phys Sportsmed. 2002;30(1):15-6.
78. Weiler JM, Layton T, Hunt, M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J Allergy Clin Immunol. 1998;102:722-6.
79. Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA. 1996;276:231-7.
80. Beckett AH, Rowland M. Rhythmic urinary excretion of amphetamine in man. Nature. 1964;204:1203-4.
81. Mikkelsen SL, Ash KO. Adulterants causing false negatives in illicit drug testing. Clin Chem. 1988;34:2333-6.
82. Dasgupta A. Urinary adulterants and drugs-of-abuse testing. Med Lab Obs. 2003;35(2):26-8,30-1.
83. Dasgupta A, Wahed A, Wells A. Rapid spot tests for detecting the presence of adulterants in urine specimens submitted for drug testing. Am J Clin Pathol. 2002;117:325-9.
84. Center for Food Safety & Applied Nutrition [Food and Drug Administration Web site]. Dietary supplements. Accessed at: www.cfsan.fda.gov/ ~dms/supplmnt.html, July 10, 2003.
85. Green GA, Catlin DH, Starcevic G. Analysis of over-the-counter dietary supplements. Clin J Sports Med. 2001;11:254-9.
86. Kamber M, Baume N, Saugy M, Rivier L. Nutritional supplements as a source for positive doping cases? Int J Sport Nutr Exerc Metab. 2001;11:258-63.
87. Catlin DH, Leder, BZ, Ahrens B, et al. Trace contamination of over-thecounter androstenedione and positive urine test results for a nandrolone metabolite. JAMA. 2000;284:2618-21.
88. Schänzer W. The International Olympic Committee. Analysis of nonhormonal nutritional supplements for anabolic-androgenic steroids-an international study. Accessed at: http://multimedia.olympic.org/pdf/en-report- 324.pdf, June 19, 2003.
89. Eachus PL. Positive drug screen for benzodiazepine due to a Chinese herbal product. J Athl Train. 1996;31:165-6.
90. United States Anti-Doping Agency. Prohibited substances. Accessed at: www.usantidoping.org/prohibited-sub/index.htm, June 6, 2003.
91. Anonymous. Creatine and Androstenedione-two "dietary supplements." Med Lett Drugs Ther. 1998;40:105-6.
92. Rasmussen BB, Volpi E. Gore DC, Wolfe RR. Androstenedione does not stimulate muscle protein anabolism in young healthy men. J Clin Endocrinol Metab. 2000;85:55-9.
93. King DS, Sharp RL, Vukovich MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA. 1999;281:2020-8.
94. Leder BZ, Longcope C, Catlin DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA. 2000;283:779-82.
95. Brown GA, Vukovich MD, Reifenrath TA, et al. Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men. Int J Sport Nutr Exerc Metab. 2000;10:340-59.
96. Brown GA, Vukovich MD, Martini ER, et al. Effects of androstenedioneherbal supplementation on serum sex hormone concentrations in 30-to 59-year-old men. Int J Vitam Nutr Res. 2001;71:293-301.
97. Earnest CP. Dietary androgen "supplements": separating substance from hype. Phys Sportsmed. 2001;29(5):63-79.
98. Mahesh VB, Greenblatt RB. The in vivo conversion of dehydroepiandrosterone and androstenedione to testosterone in the human. Act Endrocrinol. 1962;41:400-6.
99. Brown GA, Vukovich MD, Martini ER, et al. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab. 2000;85:4074-80.
100. Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc. 1999;31:1788-92.
101. National Football League Players Association. List of prohibited substances. Accessed at: www.nflpa.org/shared/bannedSubstances.htm, July 8, 2003.
102. Corrigan B. DHEA and Sport. Clin J Sport Med. 2002;12:236-41.
103. Anonymous. Dehydroepiandrosterone (DHEA). Med Lett Drugs Ther. 1996;38:91-2.
104. Brown GA, Vukovich MD, Sharp RL, et al. Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J Appl Physiol. 1999;87:2274-83.
105. Mesa JLM, Ruiz JR, Gonzalez-Gross MM, et al. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med. 2002;32:903-44.
106. Demant TW, Rhodes EC. Effects of creatine supplementation on exercise performance. Sports Med. 1999;28:49-60.
107. Greenwood M, Farris J, Kreider R, et al. Creatine supplementation patterns and perceived effects in select division I college athletes. Clin J Sport Med. 2000;10:191-4.
108. Metzel JD, Small E, Levine SR, Gershel JC. Creatine use among young athletes. Pediatrics. 2001;108:421-5.
109. Tarnopolsky MA, MacLennan DP. Creatine monohydrate supplementation enhances high-intensity exercise performance in males and females. Int J Sport Nutr. 2000;10:452-63.
110. Casey A, Constantin-Teodosiu D, Howell S, et al. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol. 1996;271:E31-7.
111. Greenhaff PL. Creatine and its application as an ergogenic aid. Int J Sport Nutr. 1995;5:S100-10.
112. Syrotuik DG, Game AB, Gillies EM, Bell GJ. Effects of creatine monohydrate supplementation during combined strength and high intensity rowing training on performance. Can J Appl Physiol. 2001;26:527-42.
113. Schroeder C, Potteiger J, Randall J, et al. The effects of creatine dietary supplementation on anterior compartment pressure in the lower leg during rest and following exercise. Clin J Sport Med. 2001;11:87-95.
114. Koch JJ. Performance-enhancing substances and their use among adolescent athletes. Pediatr Rev. 2002;23: 310-7.
115. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537-45.
116. Nightingale SL. Warning issued about street drugs containing botanical sources of ephedrine. JAMA. 1996;275:1534.
117. Josefson D. Herbal stimulant causes U.S. deaths. BMJ. 1996;312:1378-9.
118. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833-8.
119. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 2002;77:12-6.
120. Gardner SF, Franks AM, Gurley BJ, et al. Effect of a multicomponent, ephedra-containing dietary supplement (Metabolife 356) on holter monitoring and hemostatic parameters in healthy volunteers. Am J Cardiol. 2003;91:1510-3.
121. Hubbard WK. Dietary supplements containing ephedrine alkaloids; reopening of the comment periods. Fed Regist. 2003;68:10417-20.
122. Associated Press. Ephedra a factor. Coroner finds 'significant amounts' of diet supplement. Accessed at: http://sportsillustrated.cnn.com/baseball/news/ 2003/03/13/bechler-report-ap/, October 20, 2003.
123. Berardi JM, Ziegenfuss TN. Effects of ribose supplementation on repeated sprint performance in men. J Strength Cond Res. 2003;17:47-52.
124. Schnirring L. Ribose: a rising star on the supplement scene? Phys Sportsmed. 2001;29(10):49-50.
125. Assael S. Cut and run. ESPN The Magazine. 2003;06.14:40-9.
126. CNN.com. Doping "conspiracy" exposed in the U.S. Accessed at: www.cnn.com/2003/SPORT/10/16/drugs.america/index.html, October 20, 2003.
127. World Anti-Doping Agency. WADA conference in New York sheds light on the potential of gene doping. Accessed at: www.wadaama.org/en/t3.asp?p=29627&x= 1&a=58573, July 9, 2003.